|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3650 AUD | 0.00% |
|
-1.35% | -43.85% |
| 07-21 | Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter | MT |
| 07-20 | Recce Pharmaceuticals Extends Share Purchase Plan Closing Date | MT |
| Market Cap | 109M 75.71M 66.52M 62.1M 56.99M 107M 7.25B 736M 288M 3.59B 284M 278M 12.4B | P/E 2026 * |
-5.98x | P/E 2027 * | -4.29x |
|---|---|---|---|---|---|
| Enterprise Value | 115M 79.33M 69.71M 65.07M 59.72M 112M 7.6B 772M 302M 3.76B 298M 291M 13B | EV / Sales 2026 * |
14.7x | EV / Sales 2027 * | 10.7x |
| Free-Float |
60.61% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 week | -1.35% | ||
| Current month | -9.88% | ||
| 1 month | -8.75% | ||
| 3 months | -32.41% | ||
| 6 months | -43.41% | ||
| Current year | -43.85% |
| 1 week | 0.35 |  | 0.38 |
| 1 month | 0.35 | | 0.41 |
| Current year | 0.35 | | 0.73 |
| 1 year | 0.35 | | 0.73 |
| 3 years | 0.28 | | 0.76 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 27/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 29/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 30/09/2012 |
James Graham
BRD | Director/Board Member | - | 30/04/2012 |
| Director/Board Member | - | 31/08/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24/02/26 | Expiration | Chief Executive Officer | 2,250,000 | 0.7781% | ||
| 14/10/25 | Expiration | Chief Executive Officer | 745,962 | 0.3217% | ||
| 21/11/24 | Buy | Director | 1,000,000 | 0.4313% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -1.35% | -13.10% | -48.95% | 76.27M | |
| -0.87% | +4.07% | +58.64% | +166.27% | 1,089B | |
| -0.45% | +3.87% | +57.95% | +58.50% | 643B | |
| +0.04% | +4.06% | +37.84% | +76.21% | 465B | |
| -1.69% | +8.36% | +38.80% | +34.26% | 359B | |
| -0.51% | +3.35% | +39.00% | +43.76% | 303B | |
| +1.50% | +5.14% | +21.72% | +18.77% | 267B | |
| +0.79% | +4.32% | -25.07% | -36.02% | 226B | |
| -1.39% | +5.90% | +27.70% | +65.55% | 212B | |
| -1.18% | +1.83% | +16.20% | +74.32% | 167B | |
| Average | -0.31% | +4.43% | +25.97% | +45.27% | 373.12B | |
| Weighted average by Cap. | -0.48% | +5.14% | +41.05% | +81.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.78M 5.39M 4.73M 4.42M 4.06M 7.59M 516M 52.4M 20.49M 255M 20.23M 19.79M 883M | 12.5M 8.65M 7.6M 7.1M 6.51M 12.19M 829M 84.17M 32.92M 410M 32.49M 31.79M 1.42B |
| Net income | -18.29M -12.67M -11.13M -10.39M -9.54M -17.85M -1.21B -123M -48.19M -601M -47.57M -46.54M -2.08B | -25.1M -17.38M -15.28M -14.26M -13.09M -24.49M -1.67B -169M -66.12M -824M -65.27M -63.85M -2.85B |
| Net Debt | 5.24M 3.63M 3.19M 2.97M 2.73M 5.11M 347M 35.27M 13.79M 172M 13.61M 13.32M 594M | 24.96M 17.29M 15.19M 14.18M 13.01M 24.36M 1.66B 168M 65.76M 820M 64.92M 63.51M 2.83B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/07/26 | A$0.3650 | 0.00% | 35,714 |
| 28/07/26 | A$0.3650 | -2.67% | 34,989 |
| 27/07/26 | A$0.3750 | +4.17% | 134,821 |
| 24/07/26 | A$0.3600 | 0.00% | 65,425 |
| 23/07/26 | A$0.3600 | +2.86% | 213,680 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
